In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $7.30 in the last session, up 7.67% from day before closing price of $6.78. In other words, the price has increased by $7.67 from its previous closing price. On the day, 2.12 million shares were traded. DNA stock price reached its highest trading level at $7.48 during the session, while it also had its lowest trading level at $6.38.
Ratios:
We take a closer look at DNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.62 and its Current Ratio is at 5.62. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.61.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 10 ’25 when Che Austin bought 99 shares for $6.54 per share.
Che Austin bought 99 shares of DNA for $567 on Apr 09 ’25. On Apr 08 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $6.80 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 393467808 and an Enterprise Value of 209002416. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.87 while its Price-to-Book (P/B) ratio in mrq is 0.52. Its current Enterprise Value per Revenue stands at 0.921 whereas that against EBITDA is -0.503.
Stock Price History:
The Beta on a monthly basis for DNA is 1.25, which has changed by -0.8193069 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $46.00, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is -20.71%, while the 200-Day Moving Average is calculated to be -23.16%.
Shares Statistics:
According to the various share statistics, DNA traded on average about 1.68M shares per day over the past 3-months and 1709410 shares per day over the past 10 days. A total of 42.70M shares are outstanding, with a floating share count of 36.98M. Insiders hold about 32.80% of the company’s shares, while institutions hold 59.02% stake in the company. Shares short for DNA as of 1741910400 were 9976616 with a Short Ratio of 6.78, compared to 1739491200 on 8753300. Therefore, it implies a Short% of Shares Outstanding of 9976616 and a Short% of Float of 29.43.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $39.34M. It ranges from a high estimate of $41.9M to a low estimate of $37M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $37.94MFor the next quarter, 5 analysts are estimating revenue of $43.62M. There is a high estimate of $45.5M for the next quarter, whereas the lowest estimate is $41.8M.
A total of 6 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $179M, while the lowest revenue estimate was $170.97M, resulting in an average revenue estimate of $174.32M. In the same quarter a year ago, actual revenue was $227.04MBased on 6 analysts’ estimates, the company’s revenue will be $203.7M in the next fiscal year. The high estimate is $250M and the low estimate is $178.74M.
